A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

• Status: Active, not recruiting
• Trial end date: 2022-10-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated AML who are refractory to or have relapsed after first-line AML therapy as shown with overall survival (OS) compared to salvage chemotherapy. In addition, this study will evaluate safety as well as determine the overall efficacy in event-free survival (EFS) and complete remission (CR) rate of ASP2215 compared to salvage chemotherapy.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Treatments: Cytarabine; Etoposide; Etoposide phosphate; Fludarabine; Fludarabine phosphate; Lenograstim; Mitoxantrone; Sargramostim

Criteria

Inclusion Criteria:

• Subject has a diagnosis of primary AML or AML secondary to myelodysplastic syndrome (MDS) according to World Health Organization (WHO) classification as determined by pathology review at the treating institution.

• Subject is refractory to or relapsed after first-line AML therapy (with or without HSCT)

• Refractory to first-line AML therapy is defined as:

a. Subject did not achieve CR/CRi/CRp under initial therapy. A subject eligible for standard therapy must receive at least 1 cycle of an anthracycline containing induction block in standard dose for the selected induction regimen. A subject not eligible for standard therapy must have received at least 1 complete block of induction therapy seen as the optimum choice of therapy to induce remission for this subject.

• Untreated first hematologic relapse is defined as:

1. Subject must have achieved a CR/CRi/CRp with first-line treatment and has hematologic relapse.

• Subject is positive for FLT3 mutation in bone marrow or whole blood as determined by the central lab. A subject with rapidly proliferative disease and unable to wait for the central lab results can be enrolled based on a local test performed after completion of the last interventional treatment. Subjects can be enrolled from a local test result if the subjects have any of the following FLT3 mutations: FLT3-internal tandem duplication (ITD), FLT3-tyrosine kinase domain (TKD)/D835 or FLT3-TKD/I836.

• Subject has an Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.

• Subject is eligible for preselected salvage chemotherapy.

• Subject must meet the following criteria as indicated on the clinical laboratory tests:

• Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN)

• Serum total bilirubin (TBL) ≤ 1.5 x ULN

• Serum creatinine ≤ 1.5 x ULN or an estimated glomerular filtration rate of > 50 mL/min as calculated by the Modification of Diet in Renal Disease equation.

• Subject is suitable for oral administration of study drug.

• Subject agrees not to participate in another interventional study while on treatment.

Inclusion Criteria for COE:

Subject is eligible for the COE if they continue to meet all inclusion criteria from the main protocol in addition to the following when the subject is evaluated for eligibility to participate in the COE portion of the study:

• Subject has received study treatment of either LoDAC, MEC or FLAG and has no response or progressive disease.

• Subject haven't received other antileukemic therapy after EoT (hydroxyurea is allowed for the control of peripheral leukemic blasts in subjects with leukocytosis).

• Subject agrees not to participate in another interventional study while on treatment.

Exclusion Criteria:

• Subject was diagnosed as acute promyelocytic leukemia.

• Subject has BCR-ABL-positive leukemia (chronic myelogenous leukemia in blast crisis).

• Subject has AML secondary to prior chemotherapy for other neoplasms (except for MDS).

• Subject is in second or later hematologic relapse or has received salvage therapy for refractory disease.

• Subject has clinically active central nervous system leukemia..

• Subject has been diagnosed with another malignancy, unless disease-free for at least 5 years. Subjects with treated nonmelanoma skin cancer, in situ carcinoma or cervical intraepithelial neoplasia, regardless of the disease-free duration, are eligible for this study if definitive treatment for the condition has been completed. Subjects with organ-confined prostate cancer with no evidence of recurrent or progressive disease are eligible if hormonal therapy has been initiated or the malignancy has been surgically removed or treated with definitive radiotherapy.

• Subject has received prior treatment with ASP2215 or other FLT3 inhibitors (with the exception of sorafenib and midostaurin used in first-line therapy regimen as part of induction, consolidation and/or maintenance).

• Subject has clinically significant abnormality of coagulation profile, such as disseminated intravascular coagulation.

• Subject has had major surgery within 4 weeks prior to the first study dose.

• Subject has radiation therapy within 4 weeks prior to the first study dose.

• Subject has congestive heart failure New York Heart Association (NYHA) class 3 or 4 or subject with a history of congestive heart failure NYHA class 3 or 4 in the past, unless a screening echocardiogram (ECHO) performed within 1 month prior to study entry results in a left ventricular ejection fraction (LVEF) that is ≥ 45%.

• Subject with mean of triplicate Fridericia-corrected QT interval (QTcF) > 450 ms at Screening based on central reading.

• Subject with Long QT Syndrome at Screening.

• Subject with hypokalemia and hypomagnesemia at Screening (defined as values below lower limit of normal [LLN]).

• Subject requires treatment with concomitant drugs that are strong inducers of CYP3A.

• Subject requires treatment with concomitant drugs that are strong inhibitors or inducers of P-gp with the exception of drugs that are considered absolutely essential for the care of the subject.

• Subject requires treatment with concomitant drugs that target serotonin 5-hydroxytryptamine receptor 1 (5HT1R) or 5-hydroxytryptamine receptor 2B (5HT2BR) receptors or sigma nonspecific receptor with the exception of drugs that are considered absolutely essential for the care of the subject.

• Subject has an active uncontrolled infection.

• Subject is known to have human immunodeficiency virus infection.

• Subject has active hepatitis B or C or other active hepatic disorder.

• Subject has any condition which makes the subject unsuitable for study participation.

• Subject has active clinically significant (graft-versus-host disease) GVHD or is on treatment with systemic corticosteroids for GVHD.

• Subject has an FLT3 mutation other than the following: FLT3-ITD, FLT3-TKD/D835 or FLT3-TKD/I836.

Exclusion Criteria for COE:

Subject will be excluded from participation in the COE if they meet any of the exclusion criteria listed in the main protocol or when the subject is evaluated for eligibility to participate in the COE portion of the study.